Mapi-Pharma, which is developing extended-release formulations of existing drugs and generics, postponed its IPO on Tuesday. The Ness Ziona, Israel-based company was founded in 2008 and planned to list on the NASDAQ under the symbol MAPI. Aegis Capital was set to be the sole bookrunner on the deal.
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
